Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Net Asset Quality Index
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd net asset quality index. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has a Net Asset Quality Index of 88.5% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.39 Billion minus total liabilities of CN¥273.93 Million yields net assets of CN¥2.12 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 688505 net assets for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2025)
Net asset quality index of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2025. This chart shows how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 21 annual periods from 2005 to 2025. As of December 2025, the index stands at 88.5%, representing net assets of CN¥2.12 Billion against total assets of CN¥2.39 Billion CNY. Check 688505 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Net Asset Quality Index by Year (2005–2025)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd net asset quality index by year from 2005 to 2025. The table below presents the year-by-year Net Asset Quality Index for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2025, covering 21 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Shanghai Fudan-Zhangjiang Bio-Pharmaceut (688505) market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 88.5% | CN¥2.12 Billion | CN¥2.39 Billion | CN¥273.93 Million | ▼ -0.6 pp |
| 2024 | 89.1% | CN¥2.31 Billion | CN¥2.59 Billion | CN¥281.23 Million | ▲ +7.1 pp |
| 2023 | 82.0% | CN¥2.36 Billion | CN¥2.88 Billion | CN¥518.12 Million | ▲ +6.3 pp |
| 2022 | 75.7% | CN¥2.25 Billion | CN¥2.98 Billion | CN¥722.99 Million | ▼ -3.0 pp |
| 2021 | 78.7% | CN¥2.19 Billion | CN¥2.78 Billion | CN¥591.58 Million | ▼ -1.6 pp |
| 2020 | 80.3% | CN¥2.01 Billion | CN¥2.50 Billion | CN¥492.21 Million | ▲ +20.7 pp |
| 2019 | 59.6% | CN¥933.15 Million | CN¥1.56 Billion | CN¥631.68 Million | ▼ -8.4 pp |
| 2018 | 68.1% | CN¥993.28 Million | CN¥1.46 Billion | CN¥466.08 Million | ▼ -9.9 pp |
| 2017 | 77.9% | CN¥892.48 Million | CN¥1.15 Billion | CN¥252.65 Million | ▲ +0.0 pp |
| 2016 | 77.9% | CN¥873.05 Million | CN¥1.12 Billion | CN¥247.70 Million | ▲ +2.8 pp |
| 2015 | 75.1% | CN¥765.84 Million | CN¥1.02 Billion | CN¥254.43 Million | ▼ -7.0 pp |
| 2014 | 82.0% | CN¥676.42 Million | CN¥824.48 Million | CN¥148.06 Million | ▲ +6.5 pp |
| 2013 | 75.5% | CN¥565.92 Million | CN¥749.22 Million | CN¥183.29 Million | ▲ +27.1 pp |
| 2012 | 48.4% | CN¥260.11 Million | CN¥537.30 Million | CN¥277.18 Million | ▼ -7.6 pp |
| 2011 | 56.0% | CN¥201.07 Million | CN¥358.88 Million | CN¥157.81 Million | ▲ +0.6 pp |
| 2010 | 55.5% | CN¥168.71 Million | CN¥304.15 Million | CN¥135.45 Million | ▼ -0.9 pp |
| 2009 | 56.3% | CN¥168.37 Million | CN¥298.83 Million | CN¥130.46 Million | ▲ +8.5 pp |
| 2008 | 47.9% | CN¥75.88 Million | CN¥158.45 Million | CN¥82.57 Million | ▼ -6.6 pp |
| 2007 | 54.5% | CN¥71.04 Million | CN¥130.38 Million | CN¥59.34 Million | ▼ -15.6 pp |
| 2006 | 70.1% | CN¥101.70 Million | CN¥145.02 Million | CN¥43.32 Million | ▼ -16.5 pp |
| 2005 | 86.6% | CN¥123.73 Million | CN¥142.91 Million | CN¥19.18 Million | — |